clinical trial · NCT05179889
Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer
Chungnam National University Hospital·phase3·recruiting·n = 308
Colon Cancer Stage IIImFOLFIRINOXmFOLFOX 6
brief summary
A multicenter, open labeled randomized, phase II trial comparing mFOLFIRINOX and mFOLFOX6 as adjuvant treatment for high risk stage III (pT4N1/2 or pTanyN2) colon cancer
started
Jul 6, 2021
primary completion
Jul 5, 2028
completion
Mar 15, 2031
last updated
Mar 19, 2026
detailed description
After inclusion and exclusion criteria have been fulfilled and the patient consent has been obtained, the patient will be included and randomized to mFOLFIRINOX or mFOLFOX 6 with a 1:1 ratio.
Arm A: mFOLFIRINOX Arm B: mFOLFOX
official title
mFOLFIRINOX Versus mFOLFOX 6 as Adjuvant Treatment for High Risk Stage III (pT4N1/2 or pTanyN2) Colon Cancer: Multicenter, Open Labeled, Randomized, Phase II Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol